BillionToOne, Menlo Park, Calif, has closed its follow-on Series A+ funding round of $15 million with select global investors. Previous investors Hummingbird Ventures and NeoTribe Ventures led the investment round, with participation from Y Combinator, Libertus Capital, Pacific 8 Ventures, Civilization Ventures, 500 Startups Istanbul, and HOF Capital. The round brings the total funding that BillionToOne has raised to more than $32.5 million.
The new funding will be used to support commercial expansion of the company’s Unity prenatal screening test to all US states as well as research and development for future diagnostics, including liquid biopsy products.

Unity is a prenatal screen that directly assesses the baby’s risk for common and severe inherited disorders such as cystic fibrosis, spinal muscular atrophy, and hemoglobinopathies from a single tube of blood from the pregnant mother.

“Since the launch of Unity  last summer, we faced a significant demand from the prenatal providers, from community OB/GYNs to top academic institutions, throughout the United States. We are planning to expand the capacity of our CLIA-licensed laboratory by more than 20 times and our commercial team size up to 50 account executives to meet the demand,” says Oguzhan Atay, PhD, cofounder and chief executive officer of BillionToOne. “This additional funding will help us accelerate this expansion process.”

To read more, visit BillionToOne.